Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma.

MLA

Picardi, M., et al. “Liposomal‐encapsulated Doxorubicin Supercharge‐containing Front‐line Treatment Improves Response Rates in Primary Mediastinal Large B‐cell Lymphoma and Mediastinal Gray Zone Lymphoma.” Hematological Oncology, vol. 42, no. 1, Jan. 2024, pp. 1–5. EBSCOhost, https://doi.org/10.1002/hon.3242.

APA

Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A., & Pane, F. (2024). Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma. Hematological Oncology, 42(1), 1–5. https://doi.org/10.1002/hon.3242

Chicago

Picardi, M., C. Giordano, N. Pugliese, M. Mascolo, S. Varricchio, G. Troncone, E. Vigliar, et al. 2024. “Liposomal‐encapsulated Doxorubicin Supercharge‐containing Front‐line Treatment Improves Response Rates in Primary Mediastinal Large B‐cell Lymphoma and Mediastinal Gray Zone Lymphoma.” Hematological Oncology 42 (1): 1–5. doi:10.1002/hon.3242.